Quarterly report [Sections 13 or 15(d)]

Restatement of Previously Issued Quarterly Financial Statements (Unaudited)

v3.25.4
Restatement of Previously Issued Quarterly Financial Statements (Unaudited)
9 Months Ended
Sep. 30, 2025
Accounting Changes and Error Corrections [Abstract]  
Restatement of Previously Issued Quarterly Financial Statements (Unaudited)

Note 2 – Restatement of Previously Issued Quarterly Financial Statements (Unaudited)

 

As further described below, our unaudited financial statements for the quarter ended September 30, 2025 has been restated to reflect the correction of material errors.

 

Restatement Background

 

The need for the restatement arose out of the results of certain financial analysis the Company performed in the course of preparing for the audit of its December 31, 2025 financial statements. Upon reevaluation of Greenshoe Rights connected to the Series L Preferred Stock issued in May 2025, management determined that the Greenshoe Rights met the criteria for liability classification in accordance with ASC 480. Accordingly, the Greenshoe Rights required classification as a liability and marked to market at each reporting date as required under GAAP

 

 

Restatement Adjustments

 

The Company inadvertently did not classify the Greenshoe Rights as a liability, which led to accounting adjustments to correct the errors identified. The following table summarizes the effect of the errors on the Company’s balance sheet as of September 30, 2025, and on the respective statement of operations and statement of cash flows.

 

The restated balance sheet line items for the third fiscal quarter of 2025 is as follows:

 

                   
    September 30, 2025 (Unaudited)  
    As Previously Reported    

Restatement

Adjustment
   

As

Restated
 
Total Assets   $ 4,321,000     $     $ 4,321,000  
                         
Greenshoe Rights liability                  
Total Liabilities     1,321,000             1,321,000  
                         
Convertible Preferred stock     1,000             1,000  
Common stock     3,000             3,000  
Additional paid in capital     703,772,000       17,323,000       721,095,000  
Accumulated deficit     (700,779,000 )     (17,323,000 )     (718,102,000 )
Total Stockholders’ Equity (Deficit)     3,000,000             3,000,000  
Total Liabilities and Stockholders’ Equity (Deficit)   $ 4,321,000     $     $ 4,321,000  

 

The restated line items of the statement of operations for the three months ended September 30, 2025, is as follows:

 

                   
    Three Months Ended September 30, 2025 (Unaudited)  
    As Previously Reported    

Restatement

Adjustment
   

As

Restated
 
Loss from Operations   $ (3,382,000 )   $     $ (3,382,000 )
                         
Change in fair value of Greenshoe Rights liability           11,413,000       11,413,000  
Total Other Income (Expense)     268,000       11,413,000       11,681,000  
Net Loss     (3,114,000 )     11,413,000       8,299,000  
                         
Dividend on Series L Preferred Stock     (144,000 )           (144,000 )
Deemed dividend           (4,058,000 )     (4,058,000 )
Net Loss attributable to common stockholders’     (3,258,000 )     7,355,000       4,097,000  
Net Loss Per Share - Basic and Diluted   $ (0.83 )   $ 1.87     $ 1.04  
Weighted average common shares outstanding - basic and diluted     3,940,714             3,940,714  

 

The restated line items of the statement of operations for the nine months ended September 30, 2025, is as follows:

 

                   
    Nine Months Ended September 30, 2025 (Unaudited)  
    As Previously Reported    

Restatement

Adjustment
   

As

Restated
 
Loss from Operations   $ (6,827,000 )   $     $ (6,827,000 )
                         
Loss on initial recognition of Greenshoe Rights liability             (28,736,000 )     (28,736,000 )
Change in fair value of Greenshoe Rights liability           11,413,000       11,413,000  
Total Other Income (Expense)     1,504,000       (17,323,000 )     (15,819,000 )
Net Loss     (5,323,000 )     (17,323,000 )     (22,646,000 )
                         
Dividend on Series L Preferred Stock     (229,000 )           (229,000 )
Deemed dividend           (4,058,000 )     (4,058,000 )
Net Loss attributable to common stockholders’     (5,552,000 )     (21,381,000 )     (26,933,000 )
Net Loss Per Share - Basic and Diluted   $ (1.84 )   $ (7.06 )   $ (8.90 )
Weighted average common shares outstanding - basic and diluted     3,025,033             3,025,033  

 

While the adjustments changed net loss and added a change in fair value of Greenshoe Rights in the statements of cash flow statements, they did not have an impact on total net cash provided by operating activities, net cash used in investing activities, or net cash provided by (used in) financing activities for any of the applicable periods.

 

The restated line items of the statement of cash flows for the nine months ended September 30, 2025, is as follows:

 

                   
    Nine Months Ended September 30, 2025 (Unaudited)  
    As Previously Reported    

Restatement

Adjustment
   

As

Restated
 
Net Loss   $ (5,323,000 )   $ (17,323,000 )   $ (22,646,000 )
                         
Loss on initial recognition of Greenshoe Rights liability             28,736,000       28,736,000  
Change in fair value of Greenshoe Rights liability           (11,413,000 )     (11,413,000 )
Net cash used in operating activities   $ (8,893,000 )   $     $ (8,893,000 )
                         
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES                        
Reclassification of Greenshoe Rights liability to equity         $ 17,323,000     $ 17,323,000